Ranibizumab for Edema of the Macula in Diabetes: a Phase 2 Study ( The Read-2 Study)
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms READ-2
- 01 Mar 2014 Status changed from active, no longer recruiting to completed, according to results published in the Eye.
- 30 Jan 2009 Planned end date changed from 1 Jan 2009 to 1 Dec 2009, according to clinicaltrials.gov.
- 30 Jan 2009 The study duration has been extended to 36 months, according to clinicaltrials.gov.